G-Pen™ Compared to Lilly Glucagon for Hypoglycemia Rescue in Adults With Type 1 Diabetes
G-Pen™ (Glucagon Injection) Compared to Lilly Glucagon (Glucagon for Injection [RDNA Origin]) for Induced Hypoglycemia Rescue in Adults With T1D: a Phase 3 B Multi-Centered, Randomized, Controlled, Single Blind, 2-Way Crossover Study to Evaluate Efficacy and Safety
Sponsor: Integrated Medical Development
A PHASE3 clinical study on Insulin Hypoglycemia and Severe Hypoglycemia, this trial is completed. The trial is conducted by Integrated Medical Development and has accumulated 10 data snapshots since 2018. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
10 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Mar 2020 — Jan 2021 [monthly]
Completed PHASE3
▶ Show 5 earlier versions
-
Jul 2019 — Mar 2020 [monthly]
Completed PHASE3
-
Jun 2019 — Jul 2019 [monthly]
Completed PHASE3
-
Jul 2018 — Jun 2019 [monthly]
Completed PHASE3
Status: Recruiting → Completed
-
Jun 2018 — Jul 2018 [monthly]
Recruiting PHASE3
-
Mar 2018 — Jun 2018 [monthly]
Recruiting PHASE3
First recorded
Jan 2018
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Integrated Medical Development
- SGS S.A.
- Xeris Pharmaceuticals
For direct contact, visit the study record on ClinicalTrials.gov .